Amy Weinfeld Schulman

Amy Weinfeld Schulman is an American healthcare biotech venture capitalist, trained as a lawyer, who serves as a managing partner at Polaris Partners. She focuses on investing in healthcare companies and early-stage biotech start-ups. She also chairs the Board of Directors for Alnylam Pharmaceuticals (NASDAQ: ALNY) and ByHeart, and represents Polaris as a director for Kallyope, Thirty Madison, QurAlis, and Larkspur. She also practiced as a lawyer.

Early life and education Both her parents practiced law and were the first in their families to attend college. Her mother, Ann, graduated from Law School at the age of 45 and her father after he had served in the US Coast Guards.

Career Amy currently serves as a managing partner at Polaris Partners, which focuses on investing in healthcare companies and early-stage biotech start-ups. She also co-founded the Polaris Innovation Fund, which she has managed since its inception in 2017. She also represents Polaris as a director on various boards, including Thirty Madison, QurAlis, and Larkspur.

Before joining Polaris in 2014, Amy held various roles at Pfizer, beginning with general counsel and moving to the business side as president of Pfizer Nutrition and president of Pfizer Consumer Healthcare. Prior to her tenure at Pfizer, she practiced law as a partner at DLA Piper and began her career in litigation at Cleary Gottlieb Steen & Hamilton in 1991.

Philanthropy Amy is active in philanthropic circles and also serves on the Boards of Action Against Hunger, Mount Sinai Hospital (where she co-chairs the Innovations Committee), and the California Institute of Technology.